Connect your AI

CeriBell, Inc. CBLL Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Edwards LifesciencesEW

$710.1M-14.2%

Other financials

Income statement

Revenue$26.5M+29.3%

Gross profit$23.1M+28.4%

Operating income-$20.7M-46.0%

Net income-$19.7M-54.5%

EPS (diluted)-$0.52-44.4%

Balance sheet

Cash & equivalents$45.3M-70.5%

Total debt$22.1M+1.6%

Total equity$140.8M-22.2%

Total assets$178.1M-16.6%

Cash flow

Operating cash flow-$19.3M-69.2%

CapEx$125.0K-15.5%

Free cash flow-$19.4M-68.1%

Valuation

Market cap$748.61M+15.6%

Enterprise value$725.47M+40.7%

P/S7.9×-1.2×

Profitability

Gross margin87.7%+0.5pp

Operating margin-68.3%+5.5pp

Net margin-63.5%+1.0pp

FCF margin-52%-1.4pp

Returns & leverage

Return on equity-37.5%—

Debt / equity0.2×0.0×

Current ratio10.4×-6.9×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CeriBell, Inc.'s proceeds from sale and maturity of available for sale securities?: CeriBell, Inc. (CBLL) reported proceeds from sale and maturity of available for sale securities of $50M in Q1 2026.